Swedish Orphan Biovitrum ... (BIOVF)
PNK: BIOVF
· Real-Time Price · USD
30.66
0.00 (0.00%)
At close: Apr 30, 2025, 10:30 AM
0.00% (1D)
| Bid | 28.8 |
| Market Cap | 10.53B |
| Revenue (ttm) | 26.03B |
| Net Income (ttm) | 3.88B |
| EPS (ttm) | 1.19 |
| PE Ratio (ttm) | 25.76 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 32.15 |
| Volume | 100 |
| Avg. Volume (20D) | 86 |
| Open | 27.00 |
| Previous Close | 30.66 |
| Day's Range | 27.00 - 30.66 |
| 52-Week Range | 22.87 - 32.25 |
| Beta | 0.30 |
About BIOVF
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin ...
Sector Healthcare
IPO Date Jan 8, 2021
Employees 1,895
Stock Exchange PNK
Ticker Symbol BIOVF
Website https://www.sobi.com
2 months ago · seekingalpha.com
Swedish Orphan Biovitrum AB (publ) (BIOVF) Q4 2024 Earnings Call TranscriptSwedish Orphan Biovitrum AB (publ) (OTCPK:BIOVF) Q4 2024 Earnings Conference Call February 5, 2025 8:30 AM ET Company Participants Guido Oelkers - Chief Executive Officer Henrik Stenqvist - Chief Fina...